XTR003 PET Radiotracer for the Detection of Viable Myocardium

PHASE2CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

March 4, 2023

Study Completion Date

March 5, 2023

Conditions
Ischemic Heart Disease (IHD)
Interventions
DRUG

XTR003

"Enrolled subjects were required to fast for ≥ 6 hours before drug administration at rest;~1. Initial intravenous injection of 18F-FDG to each subject with a dose range of 2.0-3.0 mCi (74-111 MBq). Each patient will be imaged with PET for 10 minutes at 50-70 minutes after the injection.~2. In few minutes, a single intravenous bolus injection of XTR003 will follow and administer to each patient with a dose range of 6.0-8.0 mCi (222-296 MBq). Each patient will be immediately imaged with PET for 15 minutes."

Trial Locations (1)

300456

TEDA International Cardiovascular Hospital, Tianjin

All Listed Sponsors
lead

Sinotau Pharmaceutical Group

INDUSTRY

NCT05885854 - XTR003 PET Radiotracer for the Detection of Viable Myocardium | Biotech Hunter | Biotech Hunter